Diffuse Large B-Cell Lymphoma, NOS · line 1 · Polatuzumab vedotin + Rituximab + CHP (Pola-R-CHP), 6 cycles + 2× rituximab

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	aggressive
Linked regimen	`REG-POLA-R-CHP`

ID	`IND-DLBCL-1L-POLA-R-CHP`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-DLBCL-NOS`
Sources	`SRC-ESMO-LYMPHOMA-2025` `SRC-NCCN-BCELL-2025` `SRC-POLARIX-TILLY-2022`

Notes

STUB — pending Clinical Co-Lead sign-off. Aggressive counterpart to IND-DLBCL-1L-RCHOP. Activated by RF-DLBCL-HIGH-IPI; engine routes IPI 0-1 patients to R-CHOP standard track.

Used By

Algorithms

ALGO-DLBCL-1L - ALGO-DLBCL-1L

Contraindications

CI-LVEF-LOW-FOR-ANTHRACYCLINE - CI-LVEF-LOW-FOR-ANTHRACYCLINE

Handbook Chapters

HB-DLBCL-1L - Diffuse large B-cell lymphoma: first-line reasoning

Handbook Questions

HQ-DLBCL-1L-001 - HQ-DLBCL-1L-001

Indication

IND-DLBCL-1L-RCHOP - IND-DLBCL-1L-RCHOP